RxDoctor Payments Data

Alvaro Berrios

Family · Fallbrook, CANPI 1972654879

Payments from drug & device makers

$478in general payments, 2019–2025

Across 21 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$253
  • Mckesson Medical-surgical, Inc.$54
  • Dexcom, Inc.$49
  • Acella Pharmaceuticals, LLC$46
  • Lilly USA, LLC$25
  • Exact Sciences$19
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$253
Mckesson Medical-surgical, Inc.1$54
Dexcom, Inc.2$49
Acella Pharmaceuticals, LLC2$46
Lilly USA, LLC1$25
Exact Sciences1$19
Bayer1$18
Sunovion Pharmaceuticals Inc.1$13

How this compares

$478 in reported general payments places this provider in the 60th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$6,115
Medicare patients
35
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin269$198,763
RybelsusSemaglutide121$131,008
OzempicSemaglutide109$111,632
EliquisApixaban43$34,830
JanuviaSitagliptin Phosphate35$24,531
JanumetSitagliptin Phos/Metformin Hcl36$23,547
MounjaroTirzepatide16$18,475
TrulicityDulaglutide19$17,453
Xigduo XrDapaglifloz Propaned/Metformin28$14,716
LinzessLinaclotide22$14,020
FarxigaDapagliflozin Propanediol21$12,480
XareltoRivaroxaban19$12,377
Tresiba Flextouch U-200Insulin Degludec13$9,453
DapagliflozinDapagliflozin Propanediol16$8,959
VascepaIcosapent Ethyl30$8,853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$253$242,640230 claims
Lilly USA, LLCMounjaro, Trulicity$25$35,92835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,634 family providers in California.

Other family in Fallbrook

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →